Vadim Gladyshev
Gladyshev helped shape aging research across biological clocks, biomarkers, comparative longevity and epigenetic rejuvenation. His 790 papers have received more than 56,000 citations.
Profile
Professor of Medicine at Harvard Medical School and Brigham and Women’s Hospital whose laboratory studies the molecular causes of aging, longevity, redox biology, and interventions that can extend healthy lifespan.
Role
scientisthigh confidence
Gladyshev authored peer-reviewed aging research in Nature Aging, Nature Communications, and Aging Cell, advancing mechanisms and measurement of aging through primary scientific work.
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Future vision
8.0/ 10
Gladyshev articulates an ambitious and technically concrete vision of radically extending lifespan and healthspan by identifying robust longevity and rejuvenation signatures, screening interventions against them, and combining precision diagnostics, damage-removal therapies, metabolic targets, and replacement strategies. His roadmap and explicit attention to biological-age reversal standards and intervention risks make the vision unusually rigorous, although the evidence lacks a defined human timeline or a single consistently stated end-state program.
medium confidence
Scientific impact
9.4/ 10
Primary bibliometric evidence indicates field-defining scientific influence across redox biology and aging: an h-index of 128, more than 56,000 citations, and numerous highly cited papers spanning selenoproteins, aging clocks, biomarkers, comparative longevity, and epigenetic rejuvenation. The breadth of foundational work and sustained influence on major aging-research agendas support a near-top score.
high confidence
Capital deployed
N/A
The evidence establishes substantial scientific activity but provides no capital-deployment record to evaluate. Publications and citation impact are not substitutes for investment or donation outcomes under this dimension.
No public capital deployment activity is evidenced for this scientist: no investments or donations were found.
high confidence
Strategic taste
4.0/ 10
Gladyshev’s work shows a coherent strategy spanning comparative longevity, molecular aging signatures, biomarkers, resilience, and interventions. This suggests sound scientific taste, but the evidence does not establish that he originated unusually early or contrarian theses, led the cited projects, or made choices that were counterfactually important to the field.
low confidence
Field creation
1.0/ 10
The dimension is applicable, but the supplied evidence shows scientific collaboration and platform development rather than creation of organizations, programs, communities, protocols, categories, or funding paths that enabled the broader longevity field. The structured facts explicitly report no founded organizations or donation-created programs.
high confidence
Bravery and conviction
1.0/ 10
The dimension applies, but the supplied evidence documents scientific productivity rather than public risk-taking or conviction. Gladyshev’s extensive aging research shows sustained engagement with the field, yet none of the five specified bravery flavors is demonstrated.
high confidence
Multiplier effect
7.0/ 10
Gladyshev demonstrates substantial second-order scientific leverage through an exceptionally influential publication record and broad, cross-institutional collaborations that enable follow-on research beyond his laboratory. However, the evidence does not establish comparable leverage in organization-building, capital mobilization, policy, entrepreneurship, or public legitimacy.
medium confidence
Vision
Destination
A challenge for future studies is to identify and understand molecular underpinnings of the most robust longevity signatures, and to develop approaches that combine them to achieve the most significant lifespan extension.
Understanding mechanisms of age reduction may allow, in the future, to apply these strategies to various cells and systems, thereby radically extending lifespan and healthspan.
Path
This complexity underscores both the promise of precision nutrition approaches tailored to individual characteristics and the need for improved adherence to evidence-based dietary recommendations that measurably influence biological age and age-related disease risk.
mAge establishes a scalable framework for nominating and validating personalized longevity interventions, bridging continuous digital monitoring with molecular aging diagnostics.
This work offers new insights into the bioenergetic control of aging and positions energy metabolism as a promising target for longevity interventions.
We propose a roadmap to guide research and innovation integrating replacement and next-generation damage-removal therapeutics to modulate the ageing process in the whole body, restore biological function, and extend healthy lifespan.
We seek to develop rejuvenation signatures, by analogy to longevity signatures, and use them to screen for interventions that decrease biological age.
Publicly endorses Mortality-trained clocks capture actionable aging biology
Strategy
Gladyshev’s stated research centers on the molecular causes and signatures of aging, longevity, and redox biology [S1]. His laboratory also investigates interventions that may extend healthy lifespan [S1]. No evidence was provided about investments, donations, founded organizations, collaborators, preferred development stages, or geography. Consequently, his capital-allocation strategy, risk appetite, and investment time horizon remain unknown.
UnknownUnknownMolecular AgingLongevity MechanismsRedox BiologyHealthspan Interventions
Portfolio
Investments
No public rows yet.
Donations
No public rows yet.
Organizations founded
No public rows yet.
Scientific output
h-index128
Citations-
Papers27
Trials0
Belief evolution
Connections
Companies
Collaborators and lineage
No public rows yet.
Criticisms